


Formula I

A1

or, the open chain Formula IA



Formula IA

A1

wherein R<sup>1</sup> is hydroxy or the pharmaceutically acceptable salts thereof; and

c. a pharmaceutically acceptable carrier, vehicle or diluent.


Please Cancel Claims 2-3.

Please amend claim 5 as follows:

5. (Amended) A method for slowing the progression of atherosclerotic plaques, causing the regression of atherosclerotic plaques or managing cardiac risk, or treating atherosclerosis, hyperlipidemia, HDL elevation or angina in a mammal in need of therapeutic treatment comprising administering to said mammal a therapeutically effective amount of:

a a first compound, said first compound being [2R, 4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester; and

b. a second compound, said second compound being a compound having the



Formula I

Formula I

or, the open chain Formula IA